Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril

References

• De Backer G, Ambrosioni E, Broch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil.10(Suppl. 1), S1–S10 (2003).
   PubMed Web of Science ®Google Scholar
• White HD. Should all patients with coronary disease receive angiotensin-converting enzyme inhibitors? Lancet362(9386), 755–757 (2003).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. National Heart, Lung and Blood Institute; National High Blood Pressure Education Program Co-ordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension42(6), 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation97(14), 1411–1420 (1998).
   PubMed Web of Science ®Google Scholar
• Vincent M, Marchand B, Remond G et al. Synthesis and ACE inhibitory activity of the stereoisomers of perindopril (S-9490) and perindoprilate (S-9780). Drug Des. Discov.9(1), 11–28 (1992).
   PubMedGoogle Scholar
• Lees KR, Green ST, Reid JL. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Clin. Pharmacol. Ther.44(4), 418–425 (1988).
   PubMed Web of Science ®Google Scholar
• Devissaguet JP, Ammoury N, Devissaguet M, Perret L. Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundam. Clin. Pharmacol.4(2), 175–189 (1990).
   PubMed Web of Science ®Google Scholar
• Bree F, Nguyen P, Urien S, Resplandy G, Tillement JP. Specific and high-affinity binding of perindoprilat, but not of perindopril to blood ACE. Int. J. Clin. Pharmacol. Ther. Toxicol.30(9), 325–330 (1992).
   PubMedGoogle Scholar
• Funck-Brentano C, Lecocq B, Jaillon P et al. Effects of food on the pharmacokinetics and ACE-inhibition of perindopril in healthy volunteers. In: Recent Advances in Pharmacology and Therapeutics. Velasco M, Israel A, Romero E et al. (Eds). Elsevier Science, NY, USA, 277–280 (1989).
   Google Scholar
• Louis WJ, Workman BS, Conway EL et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. J. Cardiovasc. Pharmacol.20(3), 505–511 (1992).
   PubMed Web of Science ®Google Scholar
• Gisclon LG, Moyer M. Pharmacokinetics (PK) and pharmacodynamics (PD) of perindopril (P) and its active metabolite, perindoprilat (PL) in healthy subject. Clin. Pharmacol. Ther.51, 153 (1992) (Abstract).
   Google Scholar
• Sennesael J, Ali A, Sweny P et al. The pharmacokinetics of perindopril and its effects on serum angiotensin-converting enzyme activity in hypertensive patients with chronic renal failure. Br. J. Clin. Pharmacol.33(1), 93–99 (1992).
   PubMed Web of Science ®Google Scholar
• Verpooten GA, Genissel PM, Thomas JR, De Broe ME. Single-dose pharmcokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insuficiency. Br. J. Clin. Pharmacol.32, 187–192 (1991).
   PubMed Web of Science ®Google Scholar
• Drummer OH, Rowley K, Johnson H. Metabolism and pharmacodynamics of ACE inhibitors with special reference to perindopril. In: Pharmacology. Rand MJ, Raper C (Eds). Elsevier Science, NY, USA, 545–550 (1987).
   Google Scholar
• Thiollet M, Funck-Brentano C, Grange JD, Midavaine M, Resplandy G, Jaillon P. The pharmacokinetics of perindopril in patients with liver cirrhosis. Br. J. Clin. Pharmacol.33(3), 326–328 (1992).
   PubMed Web of Science ®Google Scholar
• Anderson PJ, Critchley JA, Tomlinson B, Resplandy G. Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. Br. J. Clin. Pharmacol.39(4), 361–368 (1995).
   PubMed Web of Science ®Google Scholar
• Bellissant E, Giudicelli JF. Pharmacokinetic–pharmacodynamic model for perindoprilat regional hemodynamic effects in healthy volunteers and in congestive heart failure patients. Br. J. Clin. Pharmacol.52(1), 25–33 (2001).
   PubMed Web of Science ®Google Scholar
• Resplandy G, Genissel P. Pharmacokinetics of perindopril in high-risk populations. J. Cardiovasc. Pharmacol.18(Suppl. 7), S9–S18 (1991).
   Google Scholar
• Flammang D, Waynberger M, Chassing A. Acute and long-term efficacy of perindopril in severe chronic congestive heart failure. Am. J. Cardiol.71(17), E48–E56 (1993).
   Google Scholar
• Brown CL, Backhouse CI, Grippat JC, Santoni JP. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin–angiotensin system in hypertensive subjects. Eur. J. Clin. Pharmacol.39(4), 327–332 (1990).
   PubMed Web of Science ®Google Scholar
• Zhuo J, Mendelsohn F, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension39(Pt 2), 634–638 (2002).
   PubMed Web of Science ®Google Scholar
• Louis WJ, Conway EL, Krum H et al. Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril. Clin. Exp. Pharmacol. Physiol.19(Suppl.), 55–60 (1992).
   Google Scholar
• Johnston C, Fabris B, Yamada H et al. Comparative studies of tissue inhibition by angiotensin-converting enzyme inhibitors. J. Hypertens.7(Suppl. 5), S11–S16 (1989).
   Google Scholar
• Bussien JP, d’Amore TF, Perret L et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin. Pharmacol. Ther.39(5), 554–558 (1986).
   PubMed Web of Science ®Google Scholar
• Jackson B, Cubela RB, Johnston CI. Inhibition of tissue angiotensin-converting enzyme by perindopril: in vivo assessment in the rat using radioinhibitor binding displacement. J. Pharmacol. Exp. Ther.245(3), 950–955 (1988).
   PubMed Web of Science ®Google Scholar
• Sakaguchi K, Jackson B, Chai SY, Mendelsohn FA, Johnson CI. Effects of perindopril on tissue angiotensin-converting enzyme activity demonstrated by quantitative in vitro autoradiography. J. Cardiovasc. Pharmacol.12(6), 710–717 (1988).
   PubMed Web of Science ®Google Scholar
• Sakaguchi K, Chai SY, Jackson B, Johnston CI, Mendelsohn FA. Differential angiotensin-converting enzyme inhibition in the brain after oral administration of perindopril demonstrated by quantitative in vitro autoradiography. Neuroendocrinology48(3), 223–228 (1988). Erratum: Neuroendocrinology49(1), 112 (1989).
   PubMed Web of Science ®Google Scholar
• Andreatta SH, Averill DB, Santos RA, Ferrario CM. The ventrolateral medulla. A new site of action of the renin–angiotensin system. Hypertension11(2 Pt 2), I163–I166 (1988).
   Web of Science ®Google Scholar
• Phillips MJ, Kimura B. Converting enzyme inhibitors and brain angiotensin. J. Cardiovasc. Pharmacol.8, 582–590 (1986).
   PubMed Web of Science ®Google Scholar
• Unger T, Genten D, Lang RE. Tissue-converting enzyme and cardiovascular actions of converting enzyme inhibitors. J. Cardiovasc. Pharmacol.8(Suppl. 10), S75–S81 (1986).
   PubMed Web of Science ®Google Scholar
• Lees KR, Reid JL. Effects of intravenous S-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects. J. Cardiovasc. Pharmacol.10(2), 129–135 (1987).
   PubMed Web of Science ®Google Scholar
• Lees KR, Reid JL. Hemodynamic and humoral effects of oral perindopril, an angiotensin-converting enzyme inhibitor, in man. Br. J. Clin. Pharmacol.23(2), 159–164 (1987).
   PubMed Web of Science ®Google Scholar
• Bidiville J, Porchet M, Bussien JP, Nussberger J, Waeber B, Brunner HR. Effect of 8-day converting enzyme inhibition on ambulatory blood-pressure recordings in normotensive volunteers. Arch. Int. Pharmacodyn. Ther.288(1), 109–119 (1987).
   PubMedGoogle Scholar
• Richer C, Thuillez C, Giudicelli JF. Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteer. J. Cardiovasc. Pharmacol.9(1), 94–102 (1987).
   PubMed Web of Science ®Google Scholar
• Dollery CT, Causon RC, Brown MJ. Long-lasting inhibition of ACE and angiotensin I pressor responses by S9490 in healthy volunteers. Ricerca Sci. Educ. Perm.34, 181–186 (1985).
   Google Scholar
• Hui Y, Dai Z, Chen X, Wang W. Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension. Chin. Med. J. (Engl).108(9), 678–681 (1995).
   PubMedGoogle Scholar
• Agabiti-Rosei E, Ambrosioni E, Finardi G et al. Perindopril versus captopril: efficacy and acceptability in an Italian multicenter trial. Am. J. Med.92, S79–S83 (1992).
   Google Scholar
• Grandi AM, Venco A, Barzizza F et al. Double-blind comparison of perindopril and captopril in hypertension effects on left ventricular morphology and function. Am. J. Hypertens.4(6), 516–520 (1991).
   PubMed Web of Science ®Google Scholar
• Agabiti-Rosei E, Cores L, Leonetti G. A double-blind assessment, perindopril vs. verapamil, of the effects on office blood pressure and 24-h ambulatory blood pressure on left ventricular morphology. Annual Meeting of the European Society of Hypertension (1995) (Abstract 106).
   Google Scholar
• Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin. Sci. (Lond)87(5), 567–574 (1994).
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension23(4), 439–449 (1994).
   PubMed Web of Science ®Google Scholar
• Squire IB, O’Kane KP, Anderson N, Reid JL. Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension36(1), 132–136 (2000).
   PubMed Web of Science ®Google Scholar
• Morishita T, Tsutsi M, Shimokawa H et al. Long-term treatment with perindopril ameliorated dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J. Pharmacol.88, 100–107 (2002).
   PubMedGoogle Scholar
• Fox KM, and the EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet362(9386), 782–788 (2003)
   PubMed Web of Science ®Google Scholar
• Ferrari R. PERTINENT: PERindopril, Thrombosis, InflammatioN, Endothelial dysfunction and Neurohormonal activation Trial, a sub-analysis of EUROPA. European Society of Cardiology Annual Congress. Munich, Germany, 28 August–1 September 2004 (Abstract 2585).
   Google Scholar
• Safar ME, London GM, Plante GE. Arterial stiffness and kidney function. Hypertension43, 163–168 (2004).
   PubMed Web of Science ®Google Scholar
• Asmar RG, Pannier B, Santoni JP et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation78, 941–950 (1988).
   PubMed Web of Science ®Google Scholar
• Thybo NK, Stephens N, Cooper A et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension25, 72–81 (1995).
   Google Scholar
• Buus NH, Bøttcher M, Jørgensen CG et al. Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or β-blockade in patients with essential hypertension. Hypertension44, 465–470 (2004).
   PubMed Web of Science ®Google Scholar
• Kool MJ, Lustermans FA, Breed JG et al. The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J. Hypertens.13(8), 839–848 (1995).
   PubMed Web of Science ®Google Scholar
• Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension36(2), 220–225 (2000).
   PubMed Web of Science ®Google Scholar
• Guérin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end stage renal failure. Circulation103(7), 987–992 (2001).
   PubMed Web of Science ®Google Scholar
• Grandi AM, Bignotti M, Gaudio G, Zanzi P, Guasti L, Venco A. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. J. Cardiovasc. Pharmacol.26(5), 737–741 (1995).
   PubMed Web of Science ®Google Scholar
• Ferrari R. Effect of ACE inhibition on myocardial ischemia. Eur. Heart J.19(Suppl. J), J30–J35 (1998).
   Google Scholar
• Moroi M, Zhang L, Yasuda T et al. Interaction of genetic deficiency of endothelial nitric oxide, gender and pregnancy in vascular response to injury in mice. J. Clin. Invest.101(6), 1225–1232 (1998).
   PubMed Web of Science ®Google Scholar
• Mancini GB, Henry GC, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation94(3), 258–265 (1996). Erratum: Circulation94(6), 1490 (1996).
   PubMed Web of Science ®Google Scholar
• Ghiadoni L, Magagna A, Versari D et al. Different effects of antihypertensive drugs on conduit artery endothelial function. Hypertension41(6), 1281–1286 (2003).
   PubMed Web of Science ®Google Scholar
• Walters MR, Reid JL. Perindopril. J. Drug Eval.1, 115–141 (2003).
   Google Scholar
• Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation94(12), 3115–3122 (1996).
   PubMed Web of Science ®Google Scholar
• Fennessy P, Campbell J, Mendelsohn F et al. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin. Exp. Pharmacol. Physiol.23(Suppl. 1), S30–S32 (1996).
   PubMedGoogle Scholar
• Candido R, Jandeleit-Dahm KA, Cao Z et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation106(2), 246–253 (2002).
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Zoppi A et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive Type 2 diabetic patients. Am. J. Hypertens.15(4 Pt 1), 316–320 (2002).
   PubMed Web of Science ®Google Scholar
• Erdem Y, Usalan C, Haznedaroglu IC et al. Effects of angiotensin-converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am. J. Hypertens.12(11 Pt 1), 1071–1076 (1999).
   PubMed Web of Science ®Google Scholar
• Yasuda G, Hasegawa K, Kuji T et al. Perindopril effects on ambulatory blood pressure: relation to sympathetic nervous activity in subjects with diabetic nephropathy. Am. J. Hypertens.17(1), 14–20 (2004).
   PubMed Web of Science ®Google Scholar
• HFSA (Heart Failure Society of America). HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction – pharmacological approaches. Congest. Heart Fail.6, 11–40 (2000).
   PubMedGoogle Scholar
• Bartels GL, van den Heuvel FM, van Veldhuisen DJ, van der Ent M, Remme WJ. Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. Am. J. Cardiol.83(3), 332–336 (1999).
   PubMed Web of Science ®Google Scholar
• Speirs C, Wagniart F, Poggi L. Perindopril postmarketing surveillance: a 12 month study in 47,351 hypertensive patients. Br. J. Clin. Pharmacol.46(1), 63–70 (1998).
   PubMed Web of Science ®Google Scholar
• Julius S, Cohn JN, Neutel J et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J. Clin. Hypertens.6(1), 10–17 (2004).
   PubMedGoogle Scholar
• Guo W, Turlapaty P, Shen Y et al. Clinical experience with perindopril in patients nonresponsive to previous antihypertensive therapy: a large US community trial. Am. J. Ther.11(3), 199–205 (2004).
   PubMedGoogle Scholar
• Cohn JN, Julius S, Neutel J et al. Clinical experience with perindopril in African–American hypertensive patients: a large USA community trial. Am. J. Hypertens.17(2), 134–138 (2004).
   PubMed Web of Science ®Google Scholar
• Fenves A, Ram CV. Are angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers becoming the treatment of choice in African–Americans? Curr. Hypertens. Rep.4(4), 286–289 (2002).
   PubMed Web of Science ®Google Scholar
• Lees KR, Reid JL, Scott MG, Hosie J, Herpin D, Santoni JP. Captopril versus perindopril: a double-blind study in essential hypertension. J. Hum. Hypertens.3(1), 17–22 (1989).
   PubMedGoogle Scholar
• Alcocer L, Campos C, Bahena JH et al. Clinical acceptability of ACE inhibitor therapy in mild-to-moderate hypertension, a comparison between perindopril and enalapril. Cardiovasc. Drugs Ther.9(3), 431–436 (1995).
   PubMed Web of Science ®Google Scholar
• Yusoff K, Razak TA, Yusof N, Rafee NM. Comparative efficacy of perindopril and enalapril once daily using 24-h ambulatory blood pressure monitoring. Int. J. Clin. Pract.53(4), 277–280 (1999).
   PubMed Web of Science ®Google Scholar
• Yoshinaga K, Saruta T, Abe K. Clinical evaluation of monotherapy with perindopril in the treatment of hypertension: a double-blind parallel comparison with enalapril. Rinshu Fyaku13, 4259–4297 (1997).
   Google Scholar
• Polonia J, Pego M. A double-blind comparison of perindopril and enalapril on 24-h control of blood pressure. Am. J. Hypertens.9, 162 (1996).
   PubMed Web of Science ®Google Scholar
• Danser AH, Santoni JP, Carre A et al. Effect of perindopril and amiloride/hydrochlorothiazide on hemodynamics and vessel wall properties of large arteries. J. Hypertens.11(Suppl. 3), 8–12 (1993).
   Google Scholar
• Zannad F, Bernaud CM, Fay R. Double-blind, randomized, multicenter comparison of the effects of amlodipine and perindopril on 24-h therapeutic coverage and beyond in patients with mild-to-moderate hypertension. General Physicians Investigators’ Group. J. Hypertens.17(1), 137–146 (1999).
   PubMed Web of Science ®Google Scholar
• Canadian Study Group on Perindopril. Once-daily perindopril versus slow release diltiazem in the treatment of mild-to-moderate essential hypertension. Can. J. Cardiol.10(Suppl. D), D8–D12 (1994).
   Google Scholar
• Thurston H, Mimran A, Zanchetti A et al. A double-blind comparison of perindopril and atenolol in essential hypertension J. Hum. Hypertens.4(5), 547–552 (1990).
   PubMed Web of Science ®Google Scholar
• Morgan TO, Louis WJ, MacDonald GJ et al. Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol. Am. J. Med.92(4B), S73–S78 (1992).
   Google Scholar
• Kuperstein R, Sasson Z. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: a randomized, double-blind, controlled study of 21 obese hypertensives. Circulation102(15), 1802–1806 (2000).
   PubMed Web of Science ®Google Scholar
• Alderman M, Arakawa K, Beilin L et al. World Health Organization–International Society of Hypertension Guidelines for the management of hypertension. Blood Press.8(Suppl.), 9–43 (1999).
   PubMedGoogle Scholar
• Williams B, Poulter NR, Brown MJ et al., for the BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br. Med. J.328(7440), 634–640 (2004).
   PubMed Web of Science ®Google Scholar
• Physician’s Desk Reference (55th Edition). Thompson Healthcare, NJ, USA (2001).
   Google Scholar
• Myers MG. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicenter Dose–Response Study Group. Can. J. Cardiol.12(11), 1191–1196 (1996).
   Google Scholar
• Tan KW, Leenen FHH. Persistence of antihypertensive effect after missed dose of perindopril. Br. J. Clin. Pharmacol.48, 628–630 (1999).
   PubMed Web of Science ®Google Scholar
• Morgan T, Anderson A. Duration of antihypertensive effect of perindopril (P), enalapril (E), and captopril. Hypertension21, 568 (1993).
   Google Scholar
• Davies MK, Gibbs CR, Lip GYH. ABC of heart failure. Management: diuretics, ACE inhibitors and nitrates. Br. Med. J.320, 428–431 (2000).
   PubMedGoogle Scholar
• Desche P, Antony I, Lerebours G, Violet I, Robert S, Weber C. Acceptability of perindopril in mild-to-moderate chronic congestive heart failure. Results of a long-term open study in 320 patients. Am. J. Cardiol.71(17), E61–E68 (1993).
   Google Scholar
• Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J.22(17), 1527–1560 (2001).
   PubMed Web of Science ®Google Scholar
• Lechat P, Garnham SP, Desche P, Bounhoure JP. Efficacy and acceptability of perindopril in mild-to-moderate chronic congestive heart failure. Am. Heart J.126(3 Pt 2), 798–806 (1993).
   PubMed Web of Science ®Google Scholar
• Bounhoure JP, Bottineau G, Lechat P, Garnham J, Lapeyre G. Value of perindopril in the treatment of chronic congestive heart failure. Multicenter double-blind placebo-controlled study. Clin. Exp. Hypertens.11(Suppl. 2), 575–586 (1989).
   Web of Science ®Google Scholar
• Squire IB, MacFayden RJ, Reid JL, Devlin A, Lees KR. Differing early blood pressure and renin–angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. J. Cardiovasc. Pharmacol.27(5), 657–666 (1996). Erratum: J. Cardiovasc. Pharmacol.28(3), 479 (1996).
   PubMed Web of Science ®Google Scholar
• Reid JL, MacFadyen RJ, Squire IB, Lees KR. Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose. Am. Heart J.126(3 Pt 2), 794–797 (1993).
   PubMed Web of Science ®Google Scholar
• Navookarasu NT, Rahman AR, Abdullah I. First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure: a Malaysian experience. Int. J. Clin. Pract.53(1), 25–30 (1999).
   PubMed Web of Science ®Google Scholar
• Anthopoulos L, Apostolou T, Bonoris P, Foussas S, Lefkos N, Zombolos S. Comparative hemodynamic responses to the first dose of short- and long-acting ACE inhibitors in patients with congestive heart failure. Curr. Med. Res. Opin.17(4), 290–297 (2001).
   PubMed Web of Science ®Google Scholar
• Vitovec J, Spinar J. First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Eur. J. Heart Fail.2(3), 299–304 (2000).
   Google Scholar
• MacFadyen RJ, Barr CS, Sturrock NDC et al. Further evidence that chronic perindopril treatment maintains neurohormonal suppression but does not lower blood pressure in chronic cardiac failure. Br. J. Clin. Pharmacol.44(1), 69–76 (1997).
   PubMed Web of Science ®Google Scholar
• Remme WJ, Swedberg K, and the Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J.22(17), 1527–1560 (2001). Erratum: Eur. Heart J.22(23), 2217–2218 (2001).
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. J. Am. Med. Assoc.275(19), 1507–1513 (1996).
   PubMed Web of Science ®Google Scholar
• Ferrari R, on behalf of the PREAMI Investigators. PREAMI: perindopril and remodeling in the elderly with acute myocardial infarction: study rationale and design. Cardiovasc. Drugs Ther.14, 671–679 (2000).
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet355, 1575–1581 (2000).
   PubMed Web of Science ®Google Scholar
• Lau CP, Tse HF, Ng W et al. Comparison of perindopril versus captopril for treatment of acute myocardial infarction. Am. J. Cardiol.89, 150–154 (2002).
   PubMed Web of Science ®Google Scholar
• Fox KM, and the EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362(9386), 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342(3), 145–153 (2000). Errata: N. Engl. J. Med.342(18), 1376 (2000); N. Engl. J. Med.342(10), 748 (2000).
   PubMed Web of Science ®Google Scholar
• Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stroke in eastern Asia. Lancet352(9143), 1801–1807 (1998).
   PubMed Web of Science ®Google Scholar
• Hartmann A, Rundek T, Mast H et al. Mortality and causes of death after first ischemic stroke: the Northern Manhattan Stroke Study. Neurology57(11), 2000–2005 (2001).
   PubMed Web of Science ®Google Scholar
• Bronnum-Hansen H, Davidsen M, Thorvaldsen P (Danish MONICA Study Group). Long-term survival and causes of death after stroke. Stroke32(9), 2131–2136 (2001).
   PubMed Web of Science ®Google Scholar
• Kelly R, Staines A, MacWalter R et al. The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study. J. Am. Coll. Cardiol.39(2), 219–224 (2002).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Effects of a perindopril-based blood-pressure-lowering regimen on cardiac outcomes amoung patients with cerebrovascular disease. Eur. Heart J.24, 475–484 (2003).
   PubMed Web of Science ®Google Scholar
• Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke35(3), 776–785 (2004). Corrected and republished in: Stroke35(4), 1024 (2004).
   PubMed Web of Science ®Google Scholar
• Chapman N, Huxley R, Anderson C et al., Writing Committee for the PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke35(1), 116–121 (2004).
   PubMed Web of Science ®Google Scholar
• Berthet K, Neal BC, Chalmers JP et al., the perindopril protection against recurrent stroke study collaborative group. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press.13(1), 7–13 (2004).
   PubMed Web of Science ®Google Scholar
• Rodgers A, Chapman N, Woodward M et al., the perindopril protection against recurrent stroke study collaborative group. Perindopril-based blood-pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. J. Hypertens.22(3), 653–659 (2004).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Effects of blood-pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Int. Med.163, 1069–1075 (2003).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Effects of a perindopril-based blood-pressure lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease. A randomized clinical trial. Stroke34, 2333–2338 (2003).
   PubMed Web of Science ®Google Scholar
• Dyker AG, Grosset DG, Lees K. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke28(3), 580–583 (1997).
   PubMed Web of Science ®Google Scholar
• Walters MR, Bolster A, Dyker AG, Lees KR. Effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease. Stroke32(2), 473–478 (2001).
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med.325, 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N. Engl. J. Med.327(10), 685–691 (1992). Erratum: N. Engl. J. Med.327(24), 1768 (1992).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med.327(10), 669–677 (1992).
   PubMed Web of Science ®Google Scholar
• AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet342(8875), 821–828 (1993).
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. TRAndolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med.333(25), 1670–1676 (1995).
   PubMed Web of Science ®Google Scholar
• Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology Guidelines for the management of arterial hypertension. J. Hypertens.21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care26(Suppl. 1), S80–S82 (2003).
   Google Scholar
• Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 36): prospective observational study. Br. Med. J.321, 412–419 (2000).
   PubMed Web of Science ®Google Scholar
• Fressinaud P, Berrut G, Gallois H. Antihypertensive action, clinical and biological acceptability of perindopril: main results in 23,460 patients with mild to moderate hypertension treated for 6 months in general practice. Ann. Cardiol. Angeiol. (Paris)42(1), 51–59 (1993).
   PubMedGoogle Scholar
• Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: a systematic review. Br. Med. J.329(7470), 828 (2004).
   PubMed Web of Science ®Google Scholar
• Kvetny J, Gregersen G, Pedersen RS. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with Type 1 diabetes mellitus. Quar. J. Med.94(2), 89–94 (2001).
   Google Scholar
• Jerums G, Allen TJ, Campbell DJ et al. Long-term comparison between perindopril and nifedipine in normotensive patients with Type 1 diabetes and microalbuminuria. Am. J. Kidney Dis.37(5), 890–899 (2001).
   PubMed Web of Science ®Google Scholar
• Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end stage renal disease. Kidney Int.36(2), 286–290 (1989).
   PubMed Web of Science ®Google Scholar
• Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end stage renal disease. Hypertension32(3), 570–574 (1998).
   PubMed Web of Science ®Google Scholar
• Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end stage renal disease. Circulation99(18), 2434–2439 (1999).
   PubMed Web of Science ®Google Scholar
• Fox KM, on behalf of the EUROPA investigators. Late breaking clinical trials: cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Scientific Sessions of the American College of Cardiology. New Orleans, LA, USA, 7–10 March 2004.
   Google Scholar
• MacFadyen RJ, Lees KR, Reid JL. Differences in first dose response to angiotensin-converting enzyme inhibition in congestive heart failure: a placebo-controlled study. Br. Heart J.66(3), 206–211 (1991).
   PubMedGoogle Scholar